New use of neuroregulation protein

Abstract

The invention expands indications of a neuregulin in cardiovascular diseases, including sinus tachycardia and chronic atrial fibrillation. When the neuregulin is given to a mammal, the electrocardiogram PR interval thereof is found to be prolonged, and the heart rate is slowed down. The effect of slowing down the heart rate of the neuregulin can be used for anti-arrhythmias, and the chronic effect on the vagus nerve activity thereof can be used for treating sinus tachycardia and chronic atrial fibrillation.

Description

technical field The present invention relates to the fields of biochemistry, molecular biology and medicine. Specifically, the present invention relates to the indications of neuregulin in the treatment of cardiovascular diseases, including antiarrhythmia, sinus tachycardia and chronic atrial fibrillation. Background of the invention Neuregulin (NRG; heregulin, HRG), also known as glial growth factor (GGF), neu differentiation factor (new differentiation factor, NDF), is a glycoprotein with a molecular weight of about 44KD. It is a ligand for the ErbB family of tyrosine kinase receptors. The neuregulin family contains 4 members: NRG1, NRG2, NRG3, NRG4. (Falls et al., Exp Cell Res. 284:14-30, 2003) Relatively little is known about the biological functions of the latter three. NRG1 plays an important role in the nervous system, heart and breast, and there is also evidence that NRG1 signaling plays a role in the development, function and pathogenesis of several other organ s...

AI Technical Summary

Problems solved by technology

The prior art is silent on the role of neuregulin in heart rate regulation, nor on the effect of neuregulin on vagal nerve activity

Images